The heterogeneity of antipsychotic response in the treatment of schizophrenia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Schizophrenia is a heterogeneous disorder in terms of patient response to antipsychotic treatment. Understanding the heterogeneity of treatment response may help to guide treatment decisions. This study was undertaken to capture inherent patterns of response to antipsychotic treatment in patients with schizophrenia, characterize the subgroups of patients with similar courses of response, and examine illness characteristics at baseline as possible predictors of response. Method: Growth mixture modeling (GMM) was applied to data from a randomized, double-blind, 12-week study of 628 patients with schizophrenia or schizo-affective disorder treated with risperidone or olanzapine. Results: Four distinct response trajectories based on Positive and Negative Syndrome Scale (PANSS) total score over 12 weeks were identified: Class 1 (420 patients, 80.6%) with moderate average baseline PANSS total score showing gradual symptom improvement; Class 2 (65 patients, 12.5%) showing rapid symptom improvement; Class 3 (24 patients, 4.6%) with high average baseline PANSS total score showing gradual symptom improvement; and Class 4 (12 patients, 2.3%) showing unsustained symptom improvement. Latent class membership of early responders (ER) and early non-responders (ENR) was determined based on 20% symptom improvement criteria at 2 weeks and ultimate responders (UR) and ultimate non-responders (UNR) based on 40% symptom improvement criteria at 12 weeks. Baseline factors with potential influence on latent class membership were identified. Conclusions: This study identified four distinct treatment response patterns with predominant representation of responders or non-responders to treatment in these classes. This heterogeneity may represent discrete endophenotypes of response to treatment with different etiologic underpinnings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
The SAGE Handbook of Quantitative Methodology for the Social Sciences
Kaplan, D. (2004) · doi:10.4135/9781412986311 · Cited by 1,454
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“Currently available medications for schizophrenia are effective for only about 50% of patients (Kerwin & Osborne, 2000 ; Lieberman et al. 2005 ; Miyamoto et al. 2005).”
BackgroundSex Differences in the Risk of Schizophrenia: Evidence From Meta-analysis
Aleman, A., Kahn, R. S., & Selten, J.-P. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.565 · Cited by 818 · cited 2×
“Psychological Medicine (2011), 41, 1291–1300. f Cambridge University Press 2010 doi:10.1017/S0033291710001893 ORIGINAL ARTICLE gender (Aleman et al. 2003) are baseline factors that have been found to be associated with poor treatment response.”
BackgroundInfluentialDelayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408 · cited 1×
“The delayed onset hypothesis proposes that response to treatment occurs after about 2–3 weeks of antipsychotic treatment (Agid et al. 2003).”
BackgroundSelf-citationAntipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161 · cited 2×
“Cognitive functioning deficits (Harvey et al. 2005), poor pre-morbid functioning (Rabinowitz et al. 2006), earlier age of onset (Meltzer et al. 1997), duration of untreated psychosis (Ucok et al. 2004 ; Perkins, 2005) and male * Address for correspondence : J. Jacob, Ph.D., Lilly Corporate Center,…”
Background
Cited by
Cognitive-behavioral therapy for medication-resistant psychosis: A meta-analytic review
Burns, A. M. N., Erickson, D. H., & Brenner, C. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300213 · Cited by 199
Increased Resting-State Gamma-Band Connectivity in First-Episode Schizophrenia
Andreou, C., Nolte, G., Leicht, G., Polomac, N., Hanganu-Opatz, I. L., Lambert, M., Engel, A. K., & Mulert, C. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu121 · Cited by 129
Gender and 5-years course of psychosis patients: focus on clinical and social variables
the PICOS Veneto Group, Comacchio, C., Lasalvia, A., Bonetto, C., Cristofalo, D., Miglietta, E., Petterlini, S., De Santi, K., Tosato, S., Riolo, R., et al. (2020) · Archives of Women's Mental Health · doi:10.1007/s00737-019-0945-3 · Cited by 18
Metadata
- Authors
- Case, M., Stauffer, V. L., Ascher-Svanum, H., Conley, R., Kapur, S., Kane, J. M., Kollack-Walker, S., Jacob, J., & Kinon, B. J.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2010-10-07
- Volume
- 41
- Issue
- 6
- Pages
- 1291-1300
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W1978194780
- Cited by
- 80
- References
- 8
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.